Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed<i>/</i>Refractory MyelofibrosisJohn Mascarenhas, Maciej Kaźmierczak, Viola Maria Popov et al.|Blood|2024Cited by 15